Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA

Approval Establishes Company's First Non-Contracted U.S. Manufacturing Operation and Strengthens Domestic and Global Supply Chain

PARSIPPANY, N.J. and BETHLEHEM, Pa., June 25, 2012 /PRNewswire/ -- Today, Daiichi Sankyo, Inc. received U.S. Food and Drug Administration (FDA) approval to package product at its first United States-based packaging facility located in Bethlehem, PA. With this approval, the Company expands its global supply chain capability, helping to ensure the supply of medicine to U.S. physicians and their patients.

At this time, the 140,000 square foot facility will package some of the Company's portfolio of marketed products for cardiovascular and metabolic therapies including treatments for hypertension and heart disease, diabetes and hyperlipidemia. Looking ahead, the facility could assume additional responsibilities related to clinical trial materials and perform formulation and analytical testing for select products.


"From facility and process design to quality control and personnel flow, we incorporated leading-edge technology in the design and development of the Bethlehem facility," said Jeff Lane, Vice President, Operations, Daiichi Sankyo, Inc. "The commissioning of this facility is a major milestone for our U.S. organization and augments our ability to manufacture and distribute quality medicines."

The plant currently employs approximately 39 full-time employees and will continue to add employees until realizing its full operational goals. Responsibilities range from Line Operators and Material Handlers to Project Engineers and Quality Specialists. Daiichi Sankyo worked with a number of regional and local business leaders and organizations, including the Governor's Action Team, Lehigh Valley Economic Development Corporation, Northampton County and City of Bethlehem to make this milestone possible.

Lane added that by expanding the Company's business operations to include manufacturing in the U.S., the Company is helping to minimize risks associated with product supply, and is able to gain greater control over the life cycle of its products, from research and development through packaging and distribution.

About Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit www.daiichisankyo.com. Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is a member of the Daiichi Sankyo Group.  For more information on Daiichi Sankyo, Inc., please visit www.dsi.com.

SOURCE Daiichi Sankyo

 
CONTACT: Marah Binder, Daiichi Sankyo, Inc., Office: +1-973.944.2253, mabinder@dsi.com

Web Site: http://www.dsi.com

 

Posted: June 2012


View comments

Hide
(web5)